Prot #265-109: Phase 2, Parallel-Arm Study of MGCD265 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor

Project: Research project

Project Details

StatusFinished
Effective start/end date3/14/16 → 3/14/19

Funding

  • Clinverse, Inc. (Prot #265-109 // Prot #265-109)
  • Mirati Therapeutics Inc. (Prot #265-109 // Prot #265-109)